二甲双胍的使用与前列腺癌风险：队列研究的荟萃分析

Metformin use and prostate cancer risk: A meta-analysis of cohort studies.

作者信息

Feng Zhaohan, Zhou Xiaofeng, Liu Naibo, Wang Jianfeng, Chen Xing, Xu Xin

机构信息

Department of Urology, China-Japan Friendship Hospital, Beijing, China.

出版信息

Medicine (Baltimore). 2019 Mar;98(12):e14955. doi: 10.1097/MD.0000000000014955.

DOI:10.1097/MD.0000000000014955

PMID:30896668

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6709307/

Abstract

BACKGROUND

The relationship between metformin use and the risk of prostate cancer is still inconclusive. Therefore, we performed a systematic review and meta-analysis of all eligible cohort studies to evaluate a potential association of metformin use with prostate cancer risk.

METHODS

A comprehensive literature search was performed in PubMed and Web of Science databases through July 2018. A DerSimonian and Laird random-effects model was applied to calculate the pooled relative risk (RR) and its 95% confidence interval (CI).

RESULTS

Eighteen cohort or nested case-control studies were included in this study with a total of 52,328 cases. In a random-effect pooled analysis, metformin use was not significantly associated with the risk of prostate cancer (RR 0.97, 95% CI 0.80-1.16, P = .711). Statistically significant heterogeneity was identified among included studies (P < .001, I = 98.1%). Sensitivity analysis indicated that no single study dominated the pooled RR.

CONCLUSION

The present large meta-analysis of cohort studies did not find an association between metformin use and prostate cancer risk.

摘要

背景

二甲双胍的使用与前列腺癌风险之间的关系仍无定论。因此，我们对所有符合条件的队列研究进行了系统评价和荟萃分析，以评估二甲双胍的使用与前列腺癌风险之间的潜在关联。

方法

截至2018年7月，在PubMed和Web of Science数据库中进行了全面的文献检索。采用DerSimonian和Laird随机效应模型计算合并相对风险（RR）及其95%置信区间（CI）。

结果

本研究纳入了18项队列或巢式病例对照研究，共52328例病例。在随机效应合并分析中，二甲双胍的使用与前列腺癌风险无显著关联（RR 0.97，95%CI 0.80-1.16，P = 0.711）。纳入研究之间存在统计学上的显著异质性（P < 0.001，I = 98.1%）。敏感性分析表明，没有单一研究主导合并RR。